Sign In
Last checked at 
20 Apr 2012 08:01
20 April 2012
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
PDMR/Director Shareholding
Allergy Therapeutics plc (AIM: AGY) announces that pursuant to the fundraising announced on 30 March 2012, which completed yesterday, the Directors of the Company have the following holdings in the Company:
Name of Director | Number of Ordinary Shares | Percentage of Issued Share Capital |
Peter Jensen | 120,000 | 0.03% |
Manuel Llobet(1) | 3,125,000 | 0.77% |
Ian Postlethwaite | 493,000 | 0.12% |
Stephen Smith | 776,513 | 0.19% |
Alejandro Weinstein Jr.(1) | 201,986,132 | 49.64% |
Ignace Goethals | 5,033,109 | 1.24% |
Virinder Nohria | 532,160 | 0.13% |
(1) Manuel Llobet and Alejandro Weinstein Jr. are members of the Concert Party described in the Circular. Further details of the Concert Party and their interests in the Company are set out in the Circular sent to Shareholders on 30 March 2012 and in a separate announcement released today via RNS.
Capitalised terms used, but not defined in this announcement, shall have the same meaning as given to them in the announcement and Circular published by the Company on 30 March 2012.
For further information:
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Nomura Code Securities | +44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw | |
FTI Consulting | +44 (0) 207 831 3113 |
Jonathan Birt/ Susan Quigley/ Simon Conway |
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
Follow the stocks
